Voyager Therapeutics,Inc. (NASDAQ:VYGR) Files An 8-K Other Events
Item 8.01 Other Events.
As previously announced, on January28, 2019, Voyager Therapeutics,Inc. (the “Company”) entered into a Collaboration and License Agreement, a Stock Purchase Agreement and an Investor Agreement, each with Neurocrine Biosciences,Inc. (“Neurocrine”). The Collaboration and License Agreement became effective on March11, 2019, upon expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. On March12, 2019, the Company received a $115.0 million upfront payment from Neurocrine under the Collaboration and License Agreement and issued and sold to Neurocrine 4,179,728 shares of the Company’s common stock at a price of $11.9625 per share, for an aggregate purchase price of approximately $50.0 million, to the Stock Purchase Agreement.
About Voyager Therapeutics,Inc. (NASDAQ:VYGR)
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain. Its products include VY-AADC01 for Advanced Parkinson’s Disease, VY-SOD101 for Monogenic amyotrophic lateral sclerosis (ALS), VY-FXN01 for Friedreich’s Ataxia, VY-HTT01 for Huntington’s Disease and VY-SMN101 for spinal muscular atrophy (SMA). VY-AADC01 consists of the AAV2 capsid, which has been used in multiple adeno-associated virus (AAV) gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the AADC transgene.